Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status

Oncology Research

Volumn 10, Issue 5, 1998, Pages 235-244

  McPake, Christina R ^a   Tillman, David M ^a   Poquette, Catherine A ^a   Olusegen George, E ^a   Houghton, Janet A ^a   Harris, Linda C ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

MDM2; Neuroblastoma; Pediatric glial tumors; Rhabdomyosarcoma

Indexed keywords

BAX PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53;

ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CHEMISTRY; CHILD; DRUG EFFECT; GLIOMA; HUMAN; MUTATION; NEUROBLASTOMA; RABBIT; RHABDOMYOSARCOMA;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CHILD; GLIOMA; HUMANS; MUTATION; NEUROBLASTOMA; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RABBITS; RHABDOMYOSARCOMA; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032238942     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Teicher, B. A. Drug Resistance in oncology. New York: Marcel Dekker, Inc.; 1992.
2. Kaye, S. B. Clinical drug resistance: The role of factors other than P-glycoprotein. Am. J. Med. 99:40S-44S; 1995.
3. Lane, D. P. p53, guardian of the genome. Nature 358:15-16; 1992.
4. Lowe, S. W.; Ruley, H. E.; Jacks, T.; Houseman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 74:957-967; 1993.
5. Fan, S.; El-Diery, W. S.; Bae, I. J. F.; Jondel, D.; Blatia, K.; Fornace, A. J.; Magrath, I.; Kohn, K. W.; O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res. 54:5824-5830; 1994.
6. Yang, B.; Eshleman, J. R.; Berger, N. A.; Markowitz, S. D. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. Clin. Cancer Res. 2:1649-1657; 1996.
7. Kohn, K. W.; Jackman, J.; O'Connor, P. M. Cell cycle control and cancer chemotherapy. J. Cell. Biochem. 54:440-452; 1994.
8. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell. Biol. 124:1-6; 1994.
9. Oltavi, Z. N.; Milliman, C. L.; Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619; 1993.
10. Oltavi, Z. N.; Korsmeyer, S. J. Checkpoints of dueling dimers foil death wishes. Cell 79:189-192; 1994.
11. Boise, L. H.; Gonzalez-Garcia, M.; Postema, C. E.; Ding, L.; Lindsten, T.; Turka, L. A.; Mao, X.; Nunez, G.; Thompson, C. B. Bcl-X, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608; 1993.
12. Kozopas, K. M.; Yang, T.; Buchan, H. L.; Zhou, P.; Craig, R. W. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. Sci. USA 90:3516-3520; 1993.
13. Reynolds, J. E.; Yang, T.; Qian, L.; Jenkinson, J. D.; Zhou, P.; Eastman, A.; Craig, R. W. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res. 54:6348-6352; 1994.
14. Chittenden, T.; Harrington, E. A.; O'Connor, R.; Flemington, C.; Lutz, R. J.; Evan, G. I.; Guild, B. C. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374:733-736; 1995.
15. Kiefer, M. C.; Brauer, M. J.; Powers, V. C.; Wu, J. J.; Umansky, S. R.; Tomei, L. D.; Barr, P. J. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 374:736-739; 1995.
16. Yin, X.-M.; Oltavi, Z. N.; Korsmeyer, S. J. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369:321-323; 1994.
17. Cheng, E. H.; Levine, B.; Boise, L. H.; Thompson, C. B.; Hardwick, J. M. Bax-independent inhibition of apoptosis by Bcl-XL. Nature 379:554-556; 1996.
18. Thompson, J.; Zamboni, W. C.; Cheshire, P. J.; Lutz, L.; Luo, X.; Li, Y.; Houghton, J. A.; Houghton, P. J. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin. Cancer Res. 3:423-431; 1997.
19. Hazelton, B. J.; Houghton, J. A.; Parham, D. M.; Douglass, E. C.; Torrance, P. M.; Holt, H.; Houghton, P. J. Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res. 47:4501-5407; 1987.
20. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254; 1976.
21. Farrow, S. N.; White, J. H. M.; Martinou, I.; Raven, T.; Pan, K.-T.; Grinham, C. J.; Martinou, J.-C.; Brown, R. Cloning of a Bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 374:731-733; 1995.
22. Zhan, Q.; Fan, S.; Bae, I.; Guillouf, C.; Liebermann, D. A.; O'Connor, P. M.; Fornace, A. J. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9:3743-3751; 1994.
23. Lehmann, E. Nonpapametrics: Statistical methods based on ranks. San Francisco, CA: Holden-Day; 1975.
24. Mashiyama, S.; Murakami, Y.; Yoshimoto, T.; Sekiya, T.; Hayoshi, K. Detection of p53 mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 6:1313-1318; 1991.
25. Sambrook, J.; Fritsch, E. F.; Maniatis, T. Molecular cloning: A laboratory manual, 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Press; 1989.
26. Thomas, A.; El Rouby, S.; Reed, J. C.; Krajewski, S.; Silber, R.; Potmesil, M.; Newcomb, E. W. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene 12:1055-1062; 1996.
27. Labrecque, S.; Matlashewski, G. J. Viability of wild-type p53-containing and p53 deficent tumor cells following anticancer treatment: The use of human papilloma virus E6 to target p53. Oncogene 11:387-392; 1995.
28. Slichenmeyer, W. J.; Nelson, W. G.; Slebos, R. J.; Kastan, M. B. Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53:4164-4168; 1993.
29. Gibson, A. A.; Harwood, F. G.; Tillman, D. M.; Houghton, J. A. Selective sensitization to DNA damaging agents in a human rhabdomyosarcoma cell line with inducible wild-type p53 overexpression. Clin. Cancer Res. 4:145-152; 1998.
30. Wassermann, K.; Markovits, J.; Jaxel, C.; Capranico, G.; Kohn, K. W.; Pommier, Y. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases 1 and II. Mol. Pharmacol. 38:38-45; 1990.
31. Chabner, B. A.; Collins, J. M. Cancer chemotherapy: Principles and practice. Philadelphia, PA: J. B. Lippincott Co.; 1990.
32. Kastan, M. B.; Onyekwere, O.; Sidransky, D.; Vogelstein, B.; Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311; 1991.
33. Kuerbitz, S. J.; Plunkett, B. S.; Walsh, W. V.; Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495; 1992.
34. Miyashita, T.; Krajewski, S.; Krajewska, M.; Wang, H. G.; Lin, H. K.; Liebermann, D. A.; Hoffman, B.; Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799-1805; 1994.
35. Miyashita, T.; Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299; 1995.
36. Miyashita, T.; Harigai, M.; Hanada, M.; Reed, J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54:3131-3135; 1994.
37. Dole, M.; Nunez, G.; Merchant, A. K.; Maybaum, J.; Rode, C. K.; Bloch, C. A.; Castle, V. P. Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma. Cancer Res. 54:3253-3259; 1994.
38. Dole, M. G.; Jasty, R.; Cooper, M. J.; Thompson, C. B.; Nunez, G.; Castle, V. P. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res. 55:2576-2582; 1995.
39. Strobel, T.; Swanson, L.; Korsmeyer, S.; Cannistra, S. A. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc. Natl. Acad. Sci. USA 93:14094-14099; 1996.
40. Dole, M. G.; Clarke, M. F.; Holman, P.; Benedict, M.; Lu, J.; Jasty, R.; Eipers, P.; Thompson, C. B.; Rode, C.; Bloch, C.; Nunez, G.; Castle, V. P. Bcl-xS enhances adenoviral vector-induced apoptosis in neuroblastoma cells. Cancer Res. 56:5734-5740; 1996.
41. Miyashita, T.; Reed, J. C. Bcl-2 gene transfer increases relative resistance of 549.1 and WEHI 7.2 lymphoid cells to death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res. 52:5407-5411; 1992.
42. Walton, M. I.; Whysong, D.; O'Connor, P. M.; Hockenberry, D.; Korsmeyer, S. J.; Kohn, K. W. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 53:1853-1861; 1993.
43. Kamesaki, S.; Kamesaki, H.; Jorgensen, T. J.; Tanizawa, A.; Pommier, Y.; Cossman, J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res. 53:4251-4256; 1993.
44. Kitada, S.; Takayama, S.; De Riel, K.; Tanaka, S.; Reed, J. C. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res. Dev. 4:71-79; 1994.
45. Castle, V. P.; Heidelberger, K. P.; Bromberg, J.; Ou, X.; Dole, M.; Nunez, G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am. J. Pathol. 143:1543-1550; 1993.
46. Ramani, P.; Lu, Q. L. Expression of bcl-2 gene product in neuroblastoma. J. Pathol. 172:273-278; 1994.
47. Ikegaki, N.; Katsumata, M.; Tsujimoto, Y.; Nakagawara, A.; Brodeur, G. M. Relationship between bcl-2 and myc gene expression in human neuroblastoma. Cancer Lett. 91:161-168; 1995.
48. Weinreb, M.; Day, P. J. R.; Niggli, F.; Raafat, F.; Mann, J. R. Bcl-2 oncoprotein in neuroblastoma. Lancet 345:992-993; 1995.
49. Zambetti, G. P.; Levine, A. J. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 7:855-865; 1993.
50. El-Deiry, W. S.; Harper, J. W.; O'Conner, P. M.; Velculescu, V. E.; Canman, C. E.; Jackman, J.; Pietenpol, J. A.; Burrell, M.; Hill, D. E.; Wang, Y.; Wiman, K. G.; Mercer, W. E.; Kastan, M. B.; Kohn, K. W.; Elledge, S. J.; Kinzler, K. W.; Vogelslein, B. WAF1/CIP1 is induced upon p53-mediated growth arrest and apoptosis. Cancer Res. 54:1169-1174; 1994.
51. Dulic, V.; Kaufmann, W. K.; Wilson, S. J.; Tlsty, T. D.; Lees, E.; Harper, J. W.; Elledge, S. J.; Reed, S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023; 1994.
52. Elbendary, A. A.; Cirisano, F. D.; Evans, A. C.; Davis, P. L.; Iglehart, J. D.; Marks, J. R.; Berchuck, A. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin. Cancer Res. 2:1571-1575; 1996.
53. Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. J. The MDM2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245; 1992.
54. Mayo, L. D.; Turchi, J. J.; Berberich, S. J. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents intereaction with p53. Cancer Res. 57:5013-5016; 1997.